Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses

Joost H C M Kreijtz; Yasemin Suezer; Gerrie de Mutsert; J M A van den Brand; G. van Amerongen; B S Schnierle; T. Kuiken; Ron A M Fouchier; Johannes Löwer; A D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan

doi:10.1016/j.vaccine.2009.03.020

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses

Joost H C M Kreijtz, Yasemin Suezer, Gerrie de Mutsert, J M A van den Brand, G. van Amerongen, B S Schnierle, T. Kuiken, Ron A M Fouchier, Johannes Löwer, A D M E Osterhaus, Gerd Sutter, Guus F Rimmelzwaan

Department of Virology, Erasmus Medical Center, Rotterdam, The Netherlands. [email protected]

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Highly pathogenic avian influenza viruses of the H5N1 subtype are responsible for an increasing number of infections in humans since 2003. More than 60% of the infections is lethal and new infections are reported frequently. In the light of the pandemic threat caused by these events the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the HA gene of an influenza A/H5N1 virus is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous influenza A/H5N1 viruses in mice. We also evaluated the recombinant MVA vector expressing the HA of influenza A/H5N1 virus A/Vietnam/1194/04 (MVA-HA-VN/04) in non-human primates. Cynomolgus macaques were immunized twice and then challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity. Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia. Therefore MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic avian influenza A/H5N1 viruses.

Original language	English
Pages (from-to)	6296-9
Number of pages	4
Journal	Vaccine
Volume	27
Issue number	45
DOIs	https://doi.org/10.1016/j.vaccine.2009.03.020
Publication status	Published - 2009

Keywords

Animals
Antibodies, Viral
Female
Hemagglutinin Glycoproteins, Influenza Virus
Influenza A Virus, H5N1 Subtype
Influenza Vaccines
Macaca fascicularis
Mice
Mice, Inbred C57BL
Orthomyxoviridae Infections
Vaccinia virus
Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2009.03.020

Cite this

Kreijtz, J. H. C. M., Suezer, Y., de Mutsert, G., van den Brand, J. M. A., van Amerongen, G., Schnierle, B. S., Kuiken, T., Fouchier, R. A. M., Löwer, J., Osterhaus, A. D. M. E., Sutter, G., & Rimmelzwaan, G. F. (2009). Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine, 27(45), 6296-9. https://doi.org/10.1016/j.vaccine.2009.03.020

@article{dea215fdb7f94739bcfc47db4e85ed0a,

title = "Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses",

abstract = "Highly pathogenic avian influenza viruses of the H5N1 subtype are responsible for an increasing number of infections in humans since 2003. More than 60% of the infections is lethal and new infections are reported frequently. In the light of the pandemic threat caused by these events the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the HA gene of an influenza A/H5N1 virus is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous influenza A/H5N1 viruses in mice. We also evaluated the recombinant MVA vector expressing the HA of influenza A/H5N1 virus A/Vietnam/1194/04 (MVA-HA-VN/04) in non-human primates. Cynomolgus macaques were immunized twice and then challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity. Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia. Therefore MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic avian influenza A/H5N1 viruses.",

keywords = "Animals, Antibodies, Viral, Female, Hemagglutinin Glycoproteins, Influenza Virus, Influenza A Virus, H5N1 Subtype, Influenza Vaccines, Macaca fascicularis, Mice, Mice, Inbred C57BL, Orthomyxoviridae Infections, Vaccinia virus, Journal Article, Research Support, Non-U.S. Gov't",

author = "Kreijtz, {Joost H C M} and Yasemin Suezer and {de Mutsert}, Gerrie and {van den Brand}, {J M A} and {van Amerongen}, G. and Schnierle, {B S} and T. Kuiken and Fouchier, {Ron A M} and Johannes L{\"o}wer and Osterhaus, {A D M E} and Gerd Sutter and Rimmelzwaan, {Guus F}",

year = "2009",

doi = "10.1016/j.vaccine.2009.03.020",

language = "English",

volume = "27",

pages = "6296--9",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "45",

}

Kreijtz, JHCM, Suezer, Y, de Mutsert, G, van den Brand, JMA, van Amerongen, G, Schnierle, BS, Kuiken, T, Fouchier, RAM, Löwer, J, Osterhaus, ADME, Sutter, G & Rimmelzwaan, GF 2009, 'Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses', Vaccine, vol. 27, no. 45, pp. 6296-9. https://doi.org/10.1016/j.vaccine.2009.03.020

TY - JOUR

T1 - Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses

AU - Kreijtz, Joost H C M

AU - Suezer, Yasemin

AU - de Mutsert, Gerrie

AU - van den Brand, J M A

AU - van Amerongen, G.

AU - Schnierle, B S

AU - Kuiken, T.

AU - Fouchier, Ron A M

AU - Löwer, Johannes

AU - Osterhaus, A D M E

AU - Sutter, Gerd

AU - Rimmelzwaan, Guus F

PY - 2009

Y1 - 2009

N2 - Highly pathogenic avian influenza viruses of the H5N1 subtype are responsible for an increasing number of infections in humans since 2003. More than 60% of the infections is lethal and new infections are reported frequently. In the light of the pandemic threat caused by these events the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the HA gene of an influenza A/H5N1 virus is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous influenza A/H5N1 viruses in mice. We also evaluated the recombinant MVA vector expressing the HA of influenza A/H5N1 virus A/Vietnam/1194/04 (MVA-HA-VN/04) in non-human primates. Cynomolgus macaques were immunized twice and then challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity. Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia. Therefore MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic avian influenza A/H5N1 viruses.

AB - Highly pathogenic avian influenza viruses of the H5N1 subtype are responsible for an increasing number of infections in humans since 2003. More than 60% of the infections is lethal and new infections are reported frequently. In the light of the pandemic threat caused by these events the rapid availability of safe and effective vaccines is desirable. Modified vaccinia virus Ankara (MVA) expressing the HA gene of an influenza A/H5N1 virus is a promising candidate vaccine that induced protective immunity against infection with homologous and heterologous influenza A/H5N1 viruses in mice. We also evaluated the recombinant MVA vector expressing the HA of influenza A/H5N1 virus A/Vietnam/1194/04 (MVA-HA-VN/04) in non-human primates. Cynomolgus macaques were immunized twice and then challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity. Immunization with MVA-HA-VN/04 induced (cross-reactive) antibodies and prevented virus replication in the upper and lower respiratory tract and the development of severe necrotizing bronchointerstitial pneumonia. Therefore MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity against highly pathogenic avian influenza A/H5N1 viruses.

KW - Animals

KW - Antibodies, Viral

KW - Female

KW - Hemagglutinin Glycoproteins, Influenza Virus

KW - Influenza A Virus, H5N1 Subtype

KW - Influenza Vaccines

KW - Macaca fascicularis

KW - Mice

KW - Mice, Inbred C57BL

KW - Orthomyxoviridae Infections

KW - Vaccinia virus

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.vaccine.2009.03.020

DO - 10.1016/j.vaccine.2009.03.020

M3 - Article

C2 - 19840663

SN - 0264-410X

VL - 27

SP - 6296

EP - 6299

JO - Vaccine

JF - Vaccine

IS - 45

ER -

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this